Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654965 | 0.83 | EGFR (0.45) | EGFRKDRSLC6A4SOS1HAO1 | |
| SCHEMBL2835404 | 0.81 | EGFR (0.40) | EGFRKDRSLC6A4HAO1CYP1A2 | |
| SCHEMBL2185810 | 0.78 | EGFR (0.43) | EGFRKDRSLC6A4HAO1PPARG | |
| SCHEMBL7420394 | 0.74 | LTA4H (0.48) | EGFRKDRSLC6A4SOS1ALDH1A1 | |
| Fluoride SCHEMBL28103700 | 0.73 | LTA4H (0.46) | EGFRKDRSLC6A4SOS1ALDH1A1 | |
| SCHEMBL31287823 | 0.73 | MAPT (0.55) | EGFRKDRSOS1CYP3A4ALDH1A1 | |
| SCHEMBL18796308 | 0.72 | EGFR (0.47) | EGFRKDRSLC6A4CYP1A2CYP2C19 | |
| SCHEMBL24364239 | 0.71 | MAOB (0.44) | EGFRKDRCYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17235692 | 0.71 | MMP2 (0.40) | EGFRKDRSLC6A4SOS1ALDH1A1 | |
| SCHEMBL29799834 | 0.71 | MMP2 (0.40) | EGFRKDRSLC6A4SOS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067891-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | ADDEX PHARMA, S.A. (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | ADDEX PHARMA, S.A. (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | ADDEX PHARMA, S.A. (CH) | 2013-06-13 | — | — | US | disclosed |
| EP-2134690-B1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2134690-B1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8299101-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators | Janssen Pharmaceuticals, Inc. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299101-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators | Janssen Pharmaceuticals, Inc. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299101-B2 | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators | Janssen Pharmaceuticals, Inc. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMECEUTICALS, INC (US) | 2010-04-22 | — | — | US | disclosed |
| EP-2134690-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107480-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099715-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR MODULATORS | GRM2, GRIK2, GRM1 | EGFR 1478/4885KDR 1879/4885SLC6A4 306/4885 |
| US-20130150412-A1 | 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR | GRM2, GRM1, GRM3 | EGFR 1401/4885KDR 1827/4885SLC6A4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.